Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
RCT (n=213) found S aureus pneumonia incidence at 30 days was not significantly lower following treatment with this monoclonal antibody targeting α toxin (5000mg dose) in patients with S aureus colonisation of lower respiratory tract on mechanical ventilation (18 vs. 26% placebo)
Source:
The Lancet Infectious Diseases
SPS commentary:
According to a commentary, it is unlikely traditional antibiotics will suffice as long-term solutions for the treatment of increasingly resistant bacterial infections and thus non-traditional therapies, including monoclonal antibodies, deserve further attention and evaluation, as they are less likely to contribute to the increasing emergence of antibiotic resistance than antibiotics. It notes these current data support the need for additional studies to evaluate them as therapeutic and preventive agents for bacterial infections. Such future studies should use non-traditional, so-called out-of-the-box endpoints and methodologies as the use of monoclonal antibodies to treat and prevent infectious diseases is a new science relative to the use of traditional antibiotics.